利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.027 秒)

    PHARMACEUTICAL CONTAINING HIF-1 ALPHA AND HIF-2 ALPHA EXPRESSION INHIBITOR
    25.
    发明申请
    PHARMACEUTICAL CONTAINING HIF-1 ALPHA AND HIF-2 ALPHA EXPRESSION INHIBITOR 有权
    包含HIF-1 ALPHA和HIF-2 ALPHA表达抑制剂的药物

    公开(公告)号：US20110213008A1

    公开(公告)日：2011-09-01

    申请号：US12672473

    申请日：2008-08-05

    申请人： Takeshi Nakajima ,  Emi Nakajima ,  Mitsuyoshi Azuma

    发明人： Takeshi Nakajima ,  Emi Nakajima ,  Mitsuyoshi Azuma

    IPC分类号： A61K31/713 ,  A61P27/02

    CPC分类号： A61K45/06 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14

    摘要： Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1α and HIF-2α, or expression vectors thereof.

    摘要翻译： 本发明提供在治疗与血管生成相关的视网膜疾病如老年性黄斑变性，糖尿病性视网膜病变等中具有高治疗效果的药物。 含有特异性抑制HIF-1α表达的物质的视网膜疾病治疗剂和特异性抑制HIF-2α表达的物质。 作为本发明的治疗剂中的活性成分的上述抑制物质是能够诱导HIF-1α和HIF-2α的RNAi，反义核酸或核酶的核酸或其表达载体。

    NEURITE FORMATION PROMOTER
    26.
    发明申请
    NEURITE FORMATION PROMOTER 有权
    神经形成促进器

    公开(公告)号：US20100144792A1

    公开(公告)日：2010-06-10

    申请号：US12596581

    申请日：2008-04-18

    申请人： Chiho Yabuta ,  Fumiko Yano ,  Mitsuyoshi Azuma

    发明人： Chiho Yabuta ,  Fumiko Yano ,  Mitsuyoshi Azuma

    IPC分类号： A61K31/4468 ,  A61P27/02

    CPC分类号： C07D211/58 ,  A61K9/0048 ,  A61K31/4468

    摘要： The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction.

    摘要翻译： 本发明提供含有N-（1-乙酰基哌啶-4-基）-4-氟苯甲酰胺或其药学上可接受的盐的促进眼组织神经发生的药剂和用于促进角膜神经发生和视网膜神经发生的试剂，其含有N-（1- - 乙酰基哌啶-4-基）-4-氟苯甲酰胺或其药学上可接受的盐。 角膜神经发生促进剂可用于改善角膜敏感性，治疗干眼症或治疗角膜上皮病。 视网膜神经发生促进剂可用于改善视觉功能障碍。

    Agent for prophylaxis and treatment of glaucoma
    27.
    发明授权
    Agent for prophylaxis and treatment of glaucoma 失效
    青光眼预防和治疗药物

    公开(公告)号：US06649625B2

    公开(公告)日：2003-11-18

    申请号：US10298674

    申请日：2002-11-19

    申请人： Mitsuyoshi Azuma ,  Yukuo Yoshida ,  Mitsunori Waki ,  Masayoshi Uehata

    发明人： Mitsuyoshi Azuma ,  Yukuo Yoshida ,  Mitsunori Waki ,  Masayoshi Uehata

    IPC分类号： A61K3144

    CPC分类号： A61K31/551 ,  A61K31/00 ,  A61K31/437 ,  A61K31/4409 ,  A61K31/4545 ,  A61K31/496 ,  Y10S514/912 ,  Y10S514/913

    摘要： An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.

    摘要翻译： 一种用于预防和治疗青光眼的药剂，其含有具有Rho激酶抑制活性的化合物，特别是用于预防和治疗青光眼的药物，其含有式（I）的化合物，其中每个符号如 规定，作为具有Rho激酶抑制活性的化合物。 用于预防和治疗本发明青光眼的药剂是用于预防和治疗青光眼的新型药剂，具有降眼压作用，视盘血流改善作用和房水流出促进作用。